Ostial Raises Funds to Accelerate Commercialization of Flash Aorto-Ostial Angioplasty System

February 8, 2023—Ostial Corporation, a private medical technology company focused on aorto-ostial interventions, announced it has raised $7.5 million in growth funding.

The company’s Flash system, which is commercially available in the United States, is a dual-balloon angioplasty catheter designed to overcome challenges of aorto-ostial stenting by delivering complete, 360° stent apposition at the ostium. Total stent apposition with Flash optimizes patient outcomes while improving reaccess for future interventions, noted the company.

Ostial, an Incept LLC portfolio company, intends to use the funds to accelerate commercialization of the Flash aorto-ostial angioplasty system by doubling its sales force, executing national programs, and expanding its clinical research and scientific advisory of its dual balloon-based system. Additionally, the company plans to commence development of the next-generation Flash system.

The funding was led by Delos Capital with participation from AMED Ventures and other existing investors.

Jon Bohane, General Manager and Chief Operating Officer of Ostial, commented in the company’s press release, “With support from Delos Capital and AMED Ventures, Ostial is on an exciting trajectory to further commercialize the Flash System, build out its sales and operation teams, accelerate the product into new and existing accounts, and advance our current Flash technology.”

Michael Lankford, Vice President of Sales and Business Development at Ostial, added, “Aorto-ostial stenting represents a growing worldwide ‘neck-to-waist’ market opportunity. With this new influx of capital, our field team will have the opportunity to cast a wider net and make the Flash system available to more physicians seeking to confidently treat challenging aorto-ostial lesions.”

Finally, Henry Chen, Managing Partner of Delos Capital, stated, “Our vision is to arm physicians with advanced innovation that uniquely addresses treatment of high-risk areas in coronary and peripheral cases. Ostial is uniquely posed to seek partnerships with other innovative, synergistic technologies that will expand its cardiovascular platform beyond Flash.”